文献速递肿瘤 PET/CT核素与放射性配体治疗

定量PSMA PET生物标志物预测177Lu-PSMA治疗前列腺癌疗效的系统综述与荟萃分析

Quantitative PSMA PET Biomarkers for Predicting Response to 177Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · J Nucl Med · 2026-06-01

该系统综述与荟萃分析纳入23项研究,评估定量PSMA PET参数对mCRPC患者接受177Lu-PSMA治疗反应的预后价值。结果显示SUVmean、肿瘤体积(TV)和总病灶(TL)PSMA是总生存期(OS)、无进展生存期和PSA反应的重要预测因子,而SUVmax和SUVpeak预测价值有限。

要点

  • SUVmean预测OS的汇总HR为0.93(95%CI 0.90-0.96),提示其与OS改善相关。
  • TV预测OS的汇总HR为1.37(95%CI 1.27-1.47),TL的HR为1.04(95%CI 1.03-1.05)。
  • SUVmax和SUVpeak对177Lu-PSMA治疗反应的预测价值有限。

核心结论

  • PSMA PET来源的SUVmean、TV和TL可作为预测mCRPC患者177Lu-PSMA治疗反应的有价值生物标志物。
  • 未来研究应将PET生物标志物与临床和生化参数整合以改善治疗决策。

研究设计与样本

  • 系统检索PubMed、Scopus、Web of Science和Embase数据库,纳入评估定量PSMA PET参数预测177Lu-PSMA治疗反应的研究。
  • 提取定量PSMA PET参数的HR和95%CI,采用随机效应荟萃分析进行合并,使用I²统计量评估异质性,漏斗图和Egger检验评估发表偏倚。
  • 共23项研究符合纳入标准。

主要发现

  • SUVmean预测OS的汇总HR为0.93(95%CI 0.90-0.96;I²=92.8%)。
  • TV预测OS的汇总HR为1.37(95%CI 1.27-1.47;I²=4.7%)。
  • TL预测OS的汇总HR为1.04(95%CI 1.03-1.05;I²=16.1%)。
  • SUVmean、TV或TL PSMA是OS、无进展生存期和PSA反应的显著预测因子。
  • SUVmax和SUVpeak的预测价值有限。

临床怎么用

  • 可利用PSMA PET定量参数SUVmean、TV和TL辅助筛选可能从177Lu-PSMA治疗中获益的mCRPC患者。
  • SUVmax和SUVpeak不宜单独作为177Lu-PSMA治疗反应的预测指标。

局限性

  • SUVmean预测OS的汇总分析异质性较高(I²=92.8%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (177Lu-PSMA-617) has emerged as a promising targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). However, response rates to therapy vary among patients. Quantitative PSMA PET biomarkers have been increasingly explored for their prognostic potential in guiding patient selection. This systematic review and meta-analysis aims to evaluate the prognostic value of PSMA PET biomarkers for response to 177Lu-PSMA therapy in patients with mCRPC. Methods: A systematic search was conducted across PubMed, Scopus, Web of Science, and Embase databases to identify studies evaluating quantitative PSMA PET parameters as predictors of response to 177Lu-PSMA therapy. Hazard ratios (HRs) and 95% CIs for quantitative PSMA PET parameters were extracted and synthesized using random-effects meta-analysis. Heterogeneity was assessed using I 2 statistics, and publication bias was evaluated via funnel plots and the Egger test. Results: A total of 23 studies met the inclusion criteria. Among PSMA PET parameters, SUVmean, tumor volume (TV), or total lesion (TL) PSMA emerged as significant predictors of overall survival (OS), progression free survival, and prostate-specific antigen response. The pooled HR for SUVmean in predicting OS was 0.93 (95% CI, 0.90-0.96; I 2 = 92.8%), whereas TV showed a HR of 1.37 (95% CI, 1.27-1.47; I 2 = 4.7%), and the TL had a HR of 1.04 (95% CI, 1.03-1.05; I 2 = 16.1%). Additionally, SUVmax and SUVpeak demonstrated limited predictive value. Conclusion: Our findings indicate that SUVmean, TV, and TL derived from PSMA PET imaging could serve as valuable biomarkers for prognosticating response to 177Lu-PSMA therapy in patients with mCRPC. Future studies should aim to integrate PET biomarkers with clinical and biochemical parameters to improve treatment decision-making.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kiani I, Siri MA, Babaei M, et al. Quantitative PSMA PET Biomarkers for Predicting Response to 177Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis. J Nucl Med. 2026. PMID: 41748296. doi:10.2967/jnumed.125.270872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。